EDMONTON, Aug. 12, 2013 /CNW/ - A new diagnostic test for pre-cancerous
polyps, PolypDx™, from Metabolomic Technologies Inc. (MTI), is moving
towards commercialization thanks to collaboration between the Alberta
government, the University of Alberta (U of A), the renowned BGI
Shenzhen (formerly Beijing Genomic Institute) and U of A spin-off
The University of Alberta research team, led by Dr. Richard Fedorak and
Dr. Haili Wang, have developed a non-invasive early diagnostic test
"PolypDx™" to detect evidence of colonic polyps, the precursor to
colorectal cancers. They have formed MTI with the assistance of
business incubator TEC Edmonton, to further develop, commercialize,
validate and market this innovative diagnostic in Alberta and global
The novelty of MTI's PolypDx™ resides with its significantly higher
detection accuracy than current fecal based tests, easier
administration, faster results and lower cost. The superior accuracy of
MTI's diagnostic test will be a game-changer in the early detection and
prevention of colorectal cancers.
With over a million dollars in total project support, PolypDx™ is
undergoing validation and clinical trials in Alberta and in China using
the large-scale population screening resources of the BGI.
"As one of the leading research universities in the country, the
University of Alberta is proud to deliver the kind of cutting-edge
research and innovation that leads to great discoveries like those of
MTI's," states Dr. Lorne Babiuk, Vice-President of Research, University
of Alberta. "We are thrilled to see the provincial government recognize
the value of this research on cancer detection at a global scale, which
is also a testament to the strength of innovation and technology found
right here in Alberta."
"This is an Alberta-developed technology that can save lives and it's
the result of the leading talent we have in our Campus Alberta and
Alberta Innovates systems," said the Honourable Thomas Lukaszuk, Deputy
Premier and Minister of Alberta Enterprise and Advanced Education.
"And, through our collaborative approach, we are bringing together the
right partners to move this knowledge from basic research into a
commercial application that will make a significant impact in health
The U of A's capabilities in metabolomics and clinical biomarkers were a
natural fit with BGI's strength in detection capabilities to co-develop
diagnostic tests for the global market.
"China is focusing on preventative medicine to avoid the burden of
managing long term chronic treatment costs, and MTI's pre-colon cancer
test aligns perfectly with our healthcare goals," says Yong Zhang, Head
of Proteomic Division, BGI. "BGI is the best positioned to co-develop
MTI's diagnostic tests for the Chinese market, assist with the
regulatory process and market the technology. We're excited to be
collaborating with the University of Alberta and MTI on technology that
will save thousands of lives."
BGI was founded in Beijing on Sept 9th, 1999 with the mission of
supporting the development of science and technology, building strong
research teams, and promoting the development of scientific partnership
in genomics and biomarker research. In 2007, BGI's headquarters was
relocated to Shenzhen as the first citizen-managed, non-profit research
institution in China. For more information, visit www.genomics.cn.
About the University of Alberta
Opened in 1908, the University of Alberta is one of Canada's largest
research-intensive universities. The University of Alberta is a Top 5
Canadian university and one of the Top 100 in the world, home to more
than 170 graduate programs, 200 undergraduate programs and 400 active
About Enterprise and Advanced Education, Government of Alberta.
Enterprise and Advanced Education provides strategic leadership in
advanced learning, workforce development, research, innovation,
commercialization, and economic development. The ministry is
cultivating the knowledge-inspired economy in Alberta by aligning
initiatives that strengthen the province's skilled workforce, increase
business start-ups, support the commercialization of technology, and
focus on solving challenges through a world-class research and
innovation system. For more information, visit www.eae.alberta.ca
About Metabolomic Technologies Inc.
Metabolomic Technologies Inc. (MTI) is a spin-off company from the
University of Alberta. The company was formed by Drs. Haili Wang and
Richard Fedorak to develop advanced metabolomic-based diagnostic tests
for the management of chronic diseases or 'high value' diagnostics.
MTI's initial focus is on developing highly novel, patented,
metabolomic-based diagnostic tests to detect adenomatous polyps and
colorectal cancer (CRC). Their flagship product, PolypDx™, a spot urine
diagnostic test, innovatively offers significantly higher sensitivity
in detecting adenomatous polyps than existing commercial tests, and
thus significantly advances the prevention of CRC. For more
information, visit www.metabolomictechnologies.ca.
Image with caption: "MTI management with BGI Shenzhen Director in Hangzhou (CNW Group/Metabolomic Technologies Inc.)". Image available at: http://photos.newswire.ca/images/download/20130812_C5226_PHOTO_EN_29768.jpg
SOURCE: Metabolomic Technologies Inc.
For further information:
Chief Executive Officer, MTI